cannabis/抗真菌藥

BACKGROUND OF THE INVENTION Field of the Invention The present invention is in the field of cannabis active compound formulation for medicinal application. Specifically, the use of formulations containing cannabis-derived compounds as medical treatments for chronic pain. Discussion of the State of

FIELD OF THE INVENTION The present invention relates to a therapeutic method for the treatment of diseases connected with the modulation of the cannabinoid peripheral receptor, comprising administering amidic derivatives of mono and bicarboxylic acids with substituted aminoalcohols or

FIELD The present invention relates to compounds by the regulation of cannabinoid receptors. More specifically, the compounds are inverse antagonists of cannabinoid receptor subtype-2, otherwise known as CB2. BACKGROUND Osteoporosis is a major metabolic bone disease that affects 44 million Americans

FIELD The present invention relates to compounds by the regulation of cannabinoid receptors. More specifically, the compounds are inverse antagonists of cannabinoid receptor subtype-2, otherwise known as CB2. BACKGROUND Osteoporosis is a major metabolic bone disease that affects 44 million Americans

FIELD OF THE INVENTION The present invention relates to the field of cannabinoids. More specifically, the present invention describes the medical use of some quinonoid derivatives of cannabinoids, as well as some such novel compounds. BACKGROUND OF THE INVENTION All publications mentioned throughout

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to flavonoid derivatives and, more particularly, to cannabis flavonoid derivatives or the pharmaceutically acceptable salt thereof that may be used in a pharmaceutical composition for preventing and treating ocular

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to flavonoid derivatives and, more particularly, to cannabis flavonoid derivatives or the pharmaceutically acceptable salt thereof that may be used in a pharmaceutical composition for preventing and treating ocular

FIELD OF THE INVENTION The present invention relates to therapeutics, and more especially cannabis based therapeutics for use in treating those known to have or be at increased risk of endometriosis and other ailments. BACKGROUND OF THE INVENTION Endometriosis is a common gynecological disorder.

BACKGROUND OF THE INVENTION Field of the Invention The present invention is in the field of therapeutic uses of the cannabis plant, and more specifically the field of therapeutic smokable products derived from cannabis. Discussion of the State of the Art Recently, multiple states have passed

FIELD OF THE INVENTION This invention relates generally to cannabinoid compounds. One embodiment of the present invention more particularly relates to cannabinoid compounds exhibiting fluorescence properties, particularly in the ultraviolet-visible wavelength ranges. BACKGROUND OF THE INVENTION The

BACKGROUND Delta-9-tetrahydrocannabinol or Delta-9 THC, the principle active component of Cannabis sativa (marijuana), is a member of a large family of lipophilic compounds (i.e., cannabinoids) that mediate physiological and psychotropic effects including regulation of appetite, immunosuppression,

BACKGROUND OF THE INVENTION Delta-9-tetrahydrocannabinol or Delta-9 THC, the principle active component of Cannabis sativa (marijuana), is a member of a large family of lipophilic compounds (i.e., cannabinoids) that mediate physiological and psychotropic effects including regulation of appetite,

BACKGROUND Delta-9-tetrahydrocannabinol or Delta-9 THC, the principle active component of Cannabis sativa (marijuana), is a member of a large family of lipophilic compounds (i.e., cannabinoids) that mediate physiological and psychotropic effects including regulation of appetite, immunosuppression,

BACKGROUND Delta-9-tetrahydrocannabinol or Delta-9 THC, the principle active component of Cannabis sativa (marijuana), is a member of a large family of lipophilic compounds (i.e., cannabinoids) that mediate physiological and psychotropic effects including regulation of appetite, immunosuppression,

BACKGROUND OF THE INVENTION Delta-9-tetrahydrocannabinol or Delta-9 THC, the principle active component of Cannabis sativa (marijuana), is a member of a large family of lipophilic compounds (i.e., cannabinoids) that mediate physiological and psychotropic effects including regulation of appetite,